DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors

Information source: Shandong University
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Ovarian Germ Cell Cancer; Ovarian Neoplasms; Ovarian Cancer

Intervention: Paclitaxel (Drug); Carboplatin (Drug); Bleomycin (Drug); Etoposide (Drug); Cisplatin (Drug)

Phase: Phase 3

Status: Active, not recruiting

Sponsored by: Beihua Kong

Official(s) and/or principal investigator(s):
Beihua Kong, Principal Investigator, Affiliation: Qilu Hospital


Investigators will conduct the trial to determine whether paclitaxel and cisplatin (PT) has the same curative effects and less adverse effects than bleomycin, etoposide and cisplatin(BEP) among newly diagnosed malignant ovarian germ cell tumor patients after surgery.

Clinical Details

Official title: A Multicenter, Prospective, Randomized Trial Comparing Paclitaxel and Carboplatin or Bleomycin, Etoposide and Cisplatin in the Treatment of Malignant Ovarian Germ Cell Tumors

Study design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Progression-free survival

Secondary outcome:

Chemotherapy related adverse effects in two arms

Tumor response rate

Overall survival

Detailed description: PRIMARY OBJECTIVES: To assess the activity of paclitaxel and carboplatin with respect to progression free survival (using bleomycin, etoposide, and cisplatin [BEP] as a reference) for newly diagnosed malignant ovarian germ cell tumors. SECONDARY OBJECTIVES: 1. To estimate the toxicity of paclitaxel and carboplatin, and bleomycin, etoposide, and cisplatin in this patient population. 2. To estimate overall survival for paclitaxel and carboplatin relative to that of BEP. 3. To evaluate response rate in the subset of patients with measurable disease. OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms. ARM 1: Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. ARM 2: Patients receive bleomycin IV per week, etoposide IV daily for days 1-5, cisplatin IV for days 1-5. Treatment repeats every 21 days for 3 or 4* courses in the absence of disease progression or unacceptable toxicity. NOTE: *Patients who have good risk will have 3 courses and those who have poor risks will have 4 courses. Patients undergo blood sample collection at baseline and periodically during study for laboratory biomarker analysis. After completion of study therapy, patients are followed up every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.


Minimum age: 12 Years. Maximum age: 70 Years. Gender(s): Female.


Inclusion Criteria:

- Age≤70 years; female, Chinese women;

- Histologically confirmed ovarian stromal tumor, including the following cell types:

- Granulosa cell tumor

- Granulosa cell-theca cell tumor

- Sertoli-Leydig cell tumor (androblastoma)

- Steroid (lipid) cell tumor

- Gynandroblastoma

- Unclassified sex cord-stromal tumor

- Sex cord tumor with annular tubules

- Newly diagnosed, stage IIA-IVB disease;

- Has undergone initial surgery (for diagnosis, staging, or cytoreduction) within

the past 8 weeks.

- May or may not have measurable residual disease.

- Laboratory tests: WBC≥4×10(9)/L, NEU≥2×10(9)/L, PLT≥80×10(9)/L, serum bilirubin≤ 1. 5

times the upper limit of normal, transaminase≤ 1. 5 times the upper limit of normal, BUN, Cr≤ normal

- Performance status: Karnofsky score≥60;

- Provide written informed consent.

Exclusion Criteria:

- With severe or uncontrolled internal disease, unable to receive surgery and/or

unsuitable for chemotherapy;

- History of organ transplantation, immune diseases;

- History of serious mental illness, a history of brain dysfunction;

- Drug abuse or a history of drug abuse;

- Suffering from other malignancies;

- Concurrently participating in other clinical trials

- Unable or unwilling to sign informed consents;

- Unable or unwilling to abide by protocol.

Locations and Contacts

Qilu Hospital of Shandong University, Jinan, Shandong 250012, China
Additional Information

Starting date: April 2015
Last updated: April 29, 2015

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017